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Introduction:
My project was a continuation of the Vascular Research Lab’s (VRL) ongoing research
at the University of Tennessee Medical Center Knoxville (UTMCK) aimed at optimizing
liposomal encapsulation efficiency of small interfering RNA (siRNA) which can be used
to silence genes to prevent a variety of disease pathologies.
Methods:
• Assay siRNA loading capacity of liposomes based on lipid concentration
• Development of a method for liposome purification
o HPLC
o HiTRAP Column

Results & Conclusion:
• siRNA loading capacity
o Higher lipid:siRNA resulted in increased encapsulation efficiency

• HPLC – did not work as expected
• HiTRAP Column – currently being optimized to be used as part of standard
operating procedures

Introduction
• Small interfering RNA (siRNA)

oUsed to silence genes to prevent disease pathologies

§ i.e. Intimal hyperplasia development & atherosclerotic plaque
formation

https://www.yourwellness4life.com/liposomalproducts-changing-drug-delivery-cellular-level/

• Liposomal delivery of siRNA

oEmerging field
omany approaches: utilize cationic synthetic lipids to promote siRNA
encapsulation within the liposomal nanoparticles
§ Immunogenicity & cytotoxicity hinders translational success

• VRL is working to develop an assembly technique to optimize
siRNA encapsulation into liposomal nanoparticle
oComprised of neutral, naturally occurring phospholipids

• Goal: to create a biocompatible nanoparticle with downstream
translational potential

siRNA Loading Capacity of
Liposomes
• Analysis was based on lipid concentration
• Varying lipid-to-siRNA weight-to-weight ratios were
used at assembly from 2.5:1 to 100:1
• The resulting siRNA encapsulation was quantified by
RiboGreen
• A fluorescent assay
• nucleotide residues are fluorescently labeled for detection

• By denaturing formed liposomes and labeling
entrapped siRNA, this would give a linear output so
that the unknown sample’s fluorescence could be
easily related to a concentration along a standard
curve.

Liposomal Purification
• High performance liquid chromatography (HPLC)

o size exclusion chromatography column (SEC) was used to separate
formed liposomes from free siRNA based on their differential size.
§ Separation should take place over 30-45 min

o By collecting the HPLC liposome fraction before siRNA elution, the
liposomes could be denatured and assayed by RiboGreen as before.

https://en.wikipedia.org/wiki/Highperformance_liquid_chromatography

• HiTRAP Column

o packed with Phenyl Sepharose High Performance material

§ strong cation exchange resin
§ can selectively retain anionic nucleotide residues of the siRNA

o
o
o
o

https://www.gelifesciences.com/en/us/shop/chr
omatography/resins/affinity-taggedprotein/histrap-hp-histidine-tagged-proteinpurification-columns-p-00250

liposomes could be manually pushed through the column
the siRNA was retained within the resin
The siRNA must then be manually eluted in a second step.
The two fractions were assayed by RiboGreen to quantify the encapsulated and free
siRNA

siRNA Loading Capacity of Liposomes Results
• loading capacity of siRNA is directly
related to lipid content
o not siRNA availability

• Higher lipid:siRNA resulted in
increased encapsulation efficiency.

Liposomal Purification Results
• HPLC

o did not work as planned
o liposomal nanoparticles formed are
<65nm in diameter
o The SEC column resolution was not
specific enough to accurately
separate free siRNA from the
nanoparticles
o HPLC peaks were overlapped and
the collection fractions could not be
accurately resolved.

• HiTRAP Column

o not an automated one-step system such
as HPLC
o manual process
o Rapid purification method
o can be performed in <60 minutes with
accurate resolution
o has the potential for scalability
o is being further optimized in the VRL for
implementation in their standard
operating procedures.

Conclusions
My research project was a continuation of the VRLs
ongoing research aimed at optimizing liposomal encapsulation
efficiency of small interfering RNA (siRNA). siRNA can be used to
silence genes to prevent a variety of disease pathologies,
including intimal hyperplasia development and atherosclerotic
plaque formation, the pathologies of primary interest in the VRL.
Liposomal delivery of siRNA is an emerging field in biomedical
engineering and research. The standardization of liposomal
encapsulation could help other laboratories utilize liposomal
siRNA delivery in their own areas of research and promote more
research in the field of liposomal nanoparticle delivery.

https://thisisorenda.com/oren
da-ultimate-pack/otropin/attachment/liposomeillustration/

Summary
Various methods were used to optimize liposomal
encapsulation efficiency:
1. Assay siRNA loading capacity of liposomes based on lipid
concentration
• Higher lipid:siRNA resulted in increased encapsulation efficiency

2. Purification of liposomes
a) HPLC

• Did not work as expected
• SEC column was not specific enough to separate free siRNA from
nanoparticles

b) HiTRAP Column

• Successful
• Now under further testing to optimize it to be used as part of standard
operating procedures going forward
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